Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

The goal of this clinical trial is to learn if the neoadjuvant therapy of iIparomlimab and Tuvonralimab plus lenvatinib works to treat hepatocellular carcinoma(HCC) patients with high risk of recurrence. It will also learn about the safety of the combination of iIparomlimab and Tuvonralimab plus lenvatinib. The main questions it aims to answer are: Does the combination therapy improve the major pathological response rate and reduce the risk of disease recurrence or progression in HCC patients? What medical problems do participants have when taking this combination regimen? Researchers will co

Trial Details

NCT ID
NCT07014150
Phase
PHASE2
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Lenvatinib
  • Iparomlimab and Tuvonralimab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • The subjects voluntarily participated in the study and agreed to sign the written informed consent. They had good compliance and cooperated with th…
  • Be at least 18 years old at the time of signing the informed consent form, with no gender restrictions.
  • Hepatocellular carcinoma diagnosed by histology or imaging
  • At least one measurable lesion (according to the requirements of RECIST version 1.1, the long diameter of the measurable lesion on spiral CT scan i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →